Clinical outcomes of PRESERFLO <sup>®</sup> Microshunt procedure with mitomycin C alone versus with mitomycin C and bevacizumab
Adjuvant use of bevacizumab in MMC-augmented PRESERFLO Microshunt procedure is at least as effective as MMC alone but helps reduce rates of postoperative interventions.
Authors
- Lee Jones (ORCID: https://orcid.org/0000-0002-8030-1211)
- Umair Qidwai
- Gokulan Ratnarajan (ORCID: https://orcid.org/0000-0001-7990-5053)
- Inas Gadelkarim (ORCID: https://orcid.org/0000-0001-9442-0177)
Institutions
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- Queen Victoria Hospital (GB)
- Queen Victoria Hospital NHS Foundation Trust (GB)
- University College London (GB)
- Alexandria University (EG)
Publication Details
- Journal
- Therapeutic Advances in Ophthalmology
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1177/25158414241287421
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00